Brensocatib Becomes First FDA-Approved Therapy for Bronchiectasis
Brensocatib (Brinsupri; Insmed) gains FDA approval as the first treatment for bronchiectasis, offering hope to patients with the chronic lung disease.
Previous Post
PureTech launches new biotech built around lung disease drug
Next Post
ACMT Toxicology Visual Pearl – Lead it Be?
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago